<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;utm_source=Chrome&amp;ff=20240405001211&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.18.0.post9+e462414&amp;fc=20230708114047&amp;utm_campaign=pubmed-2
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;utm_source=Chrome&amp;ff=20240405001211&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.18.0.post9+e462414&amp;fc=20230708114047&amp;utm_campaign=pubmed-2" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Fri, 05 Apr 2024 04:12:11 +0000</lastbuilddate>
<pubDate>Thu, 04 Apr 2024 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>Modernizing Cardiovascular Medicine Board Certification: Leveraging Innovation and Strengthening Continuous Competency and Professional Growth</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38573283/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240405001211&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Mar 13:S0735-1097(24)00473-X. doi: 10.1016/j.jacc.2024.02.034. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38573283/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240405001211&v=2.18.0.post9+e462414">38573283</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.02.034>10.1016/j.jacc.2024.02.034</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38573283</guid>
<pubDate>Thu, 04 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>B Hadley Wilson</dc:creator>
<dc:creator>Joseph C Wu</dc:creator>
<dc:creator>James C Fang</dc:creator>
<dc:creator>Jodie L Hurwitz</dc:creator>
<dc:creator>George D Dangas</dc:creator>
<dc:date>2024-04-04</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Modernizing Cardiovascular Medicine Board Certification: Leveraging Innovation and Strengthening Continuous Competency and Professional Growth</dc:title>
<dc:identifier>pmid:38573283</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.02.034</dc:identifier>
</item>
<item>
<title>Association of Disrupted Delta Wave Activity During Sleep With Long-Term Cardiovascular Disease and Mortality</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38573282/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240405001211&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Our results suggest that delta wave activity disruption during sleep may be a useful metric to identify those at increased risk for CVD and CVD mortality.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Mar 28:S0735-1097(24)00484-4. doi: 10.1016/j.jacc.2024.02.040. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Delta wave activity is a prominent feature of deep sleep, which is significantly associated with sleep quality.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The authors hypothesized that delta wave activity disruption during sleep could predict long-term cardiovascular disease (CVD) and CVD mortality risk.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We used a comprehensive power spectral entropy-based method to assess delta wave activity during sleep based on overnight polysomnograms in 4,058 participants in the SHHS (Sleep Heart Health Study) and 2,193 participants in the MrOS (Osteoporotic Fractures in Men Study) Sleep study.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: During 11.0 ± 2.8 years of follow-up in SHHS, 729 participants had incident CVD and 192 participants died due to CVD. During 15.5 ± 4.4 years of follow-up in MrOS, 547 participants had incident CVD, and 391 died due to CVD. In multivariable Cox regression models, lower delta wave entropy during sleep was associated with higher risk of coronary heart disease (SHHS: HR: 1.46; 95% CI: 1.02-2.06; P = 0.03; MrOS: HR: 1.79; 95% CI: 1.17-2.73; P &lt; 0.01), CVD (SHHS: HR: 1.60; 95% CI: 1.21-2.11; P &lt; 0.01; MrOS: HR: 1.43; 95% CI: 1.00-2.05; P = 0.05), and CVD mortality (SHHS: HR: 1.94; 95% CI: 1.18-3.18; P &lt; 0.01; MrOS: HR: 1.66; 95% CI: 1.12-2.47; P = 0.01) after adjusting for covariates. The Shapley Additive Explanations method indicates that low delta wave entropy was more predictive of coronary heart disease, CVD, and CVD mortality risks than conventional sleep parameters.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Our results suggest that delta wave activity disruption during sleep may be a useful metric to identify those at increased risk for CVD and CVD mortality.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38573282/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240405001211&v=2.18.0.post9+e462414">38573282</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.02.040>10.1016/j.jacc.2024.02.040</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38573282</guid>
<pubDate>Thu, 04 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Sizhi Ai</dc:creator>
<dc:creator>Shuo Ye</dc:creator>
<dc:creator>Guohua Li</dc:creator>
<dc:creator>Yue Leng</dc:creator>
<dc:creator>Katie L Stone</dc:creator>
<dc:creator>Min Zhang</dc:creator>
<dc:creator>Yun-Kwok Wing</dc:creator>
<dc:creator>Jihui Zhang</dc:creator>
<dc:creator>Yannis Yan Liang</dc:creator>
<dc:date>2024-04-04</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Association of Disrupted Delta Wave Activity During Sleep With Long-Term Cardiovascular Disease and Mortality</dc:title>
<dc:identifier>pmid:38573282</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.02.040</dc:identifier>
</item>
<item>
<title>Catheter-based therapy for high-risk or intermediate-risk pulmonary embolism: death and re-hospitalization</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38573048/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240405001211&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Among patients with high-risk or intermediate-risk PE, CBT was associated with lower in-hospital death and 90-day readmission. Prospective, randomized trials are needed to confirm these findings.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Apr 4:ehae184. doi: 10.1093/eurheartj/ehae184. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Catheter-based therapies (CBTs) have been developed as a treatment option in patients with pulmonary embolism (PE). There remains a paucity of data to inform decision-making in patients with intermediate-risk or high-risk PE. The aim of this study was to characterize in-hospital and readmission outcomes in patients with intermediate-risk or high-risk PE treated with vs. without CBT in a large retrospective registry.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Patients hospitalized with intermediate-risk or high-risk PE were identified using the 2017-20 National Readmission Database. In-hospital outcomes included death and bleeding and 30- and 90-day readmission outcomes including all-cause, venous thromboembolism (VTE)-related and bleeding-related readmissions. Inverse probability of treatment weighting (IPTW) was utilized to compare outcomes between CBT and no CBT.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 14 903 [2076 (13.9%) with CBT] and 42 829 [8824 (20.6%) with CBT] patients with high-risk and intermediate-risk PE were included, respectively. Prior to IPTW, patients with CBT were younger and less likely to have cancer and cardiac arrest, receive systemic thrombolysis, or be on mechanical ventilation. In the IPTW logistic regression model, CBT was associated with lower odds of in-hospital death in high-risk [odds ratio (OR) 0.83, 95% confidence interval (CI) 0.80-0.87] and intermediate-risk PE (OR 0.76, 95% CI 0.70-0.83). Patients with high-risk PE treated with CBT were associated with lower risk of 90-day all-cause [hazard ratio (HR) 0.77, 95% CI 0.71-0.83] and VTE (HR 0.46, 95% CI 0.34-0.63) readmission. Patients with intermediate-risk PE treated with CBT were associated with lower risk of 90-day all-cause (HR 0.75, 95% CI 0.72-0.79) and VTE (HR 0.66, 95% CI 0.57-0.76) readmission.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Among patients with high-risk or intermediate-risk PE, CBT was associated with lower in-hospital death and 90-day readmission. Prospective, randomized trials are needed to confirm these findings.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38573048/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240405001211&v=2.18.0.post9+e462414">38573048</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae184>10.1093/eurheartj/ehae184</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38573048</guid>
<pubDate>Thu, 04 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Orly Leiva</dc:creator>
<dc:creator>Carlos Alviar</dc:creator>
<dc:creator>Sameer Khandhar</dc:creator>
<dc:creator>Sahil A Parikh</dc:creator>
<dc:creator>Catalin Toma</dc:creator>
<dc:creator>Radu Postelnicu</dc:creator>
<dc:creator>James Horowitz</dc:creator>
<dc:creator>Vikramjit Mukherjee</dc:creator>
<dc:creator>Allison Greco</dc:creator>
<dc:creator>Sripal Bangalore</dc:creator>
<dc:date>2024-04-04</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Catheter-based therapy for high-risk or intermediate-risk pulmonary embolism: death and re-hospitalization</dc:title>
<dc:identifier>pmid:38573048</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae184</dc:identifier>
</item>
<item>
<title>Alain Cribier (1945-2024)</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38570709/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240405001211&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2024 Apr 3. doi: 10.1038/s41569-024-01019-9. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38570709/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240405001211&v=2.18.0.post9+e462414">38570709</a> | DOI:<a href=https://doi.org/10.1038/s41569-024-01019-9>10.1038/s41569-024-01019-9</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38570709</guid>
<pubDate>Wed, 03 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Martine Gilard</dc:creator>
<dc:creator>William Wijns</dc:creator>
<dc:date>2024-04-03</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Alain Cribier (1945-2024)</dc:title>
<dc:identifier>pmid:38570709</dc:identifier>
<dc:identifier>doi:10.1038/s41569-024-01019-9</dc:identifier>
</item>
<item>
<title>Reply: Echocardiographic mPAP/CO Slope: Limitations and Strengths of a Noninvasive Tool for Assessing Exercise Pulmonary Hemodynamics</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38569770/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240405001211&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Apr 9;83(14):e143-e144. doi: 10.1016/j.jacc.2024.02.008.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38569770/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240405001211&v=2.18.0.post9+e462414">38569770</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.02.008>10.1016/j.jacc.2024.02.008</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38569770</guid>
<pubDate>Wed, 03 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Luna Gargani</dc:creator>
<dc:creator>Nicola Riccardo Pugliese</dc:creator>
<dc:creator>Matteo Mazzola</dc:creator>
<dc:creator>Robert Naeije</dc:creator>
<dc:creator>Eduardo Bossone</dc:creator>
<dc:date>2024-04-03</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Reply: Echocardiographic mPAP/CO Slope: Limitations and Strengths of a Noninvasive Tool for Assessing Exercise Pulmonary Hemodynamics</dc:title>
<dc:identifier>pmid:38569770</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.02.008</dc:identifier>
</item>
<item>
<title>Exercise Echocardiography for mPAP/CO Slope Estimation: A New Standard for Routine Clinical Care?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38569769/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240405001211&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Apr 9;83(14):e141-e142. doi: 10.1016/j.jacc.2023.12.039.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38569769/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240405001211&v=2.18.0.post9+e462414">38569769</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.12.039>10.1016/j.jacc.2023.12.039</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38569769</guid>
<pubDate>Wed, 03 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Youri Bekhuis</dc:creator>
<dc:creator>Jan Verwerft</dc:creator>
<dc:creator>Guido Claessen</dc:creator>
<dc:date>2024-04-03</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Exercise Echocardiography for mPAP/CO Slope Estimation: A New Standard for Routine Clinical Care?</dc:title>
<dc:identifier>pmid:38569769</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.12.039</dc:identifier>
</item>
<item>
<title>Echocardiographic Estimation of Systolic Pulmonary Artery Pressure at Rest and During Stress</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38569768/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240405001211&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Apr 9;83(14):e139. doi: 10.1016/j.jacc.2023.12.040.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38569768/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240405001211&v=2.18.0.post9+e462414">38569768</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.12.040>10.1016/j.jacc.2023.12.040</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38569768</guid>
<pubDate>Wed, 03 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Francisco Gual-Capllonch</dc:creator>
<dc:date>2024-04-03</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Echocardiographic Estimation of Systolic Pulmonary Artery Pressure at Rest and During Stress</dc:title>
<dc:identifier>pmid:38569768</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.12.040</dc:identifier>
</item>
<item>
<title>Challenges in Noninvasive Cardiac Output Assessment During Exercise</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38569767/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240405001211&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Apr 9;83(14):e137-e138. doi: 10.1016/j.jacc.2023.12.038.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38569767/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240405001211&v=2.18.0.post9+e462414">38569767</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.12.038>10.1016/j.jacc.2023.12.038</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38569767</guid>
<pubDate>Wed, 03 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Mads Jønsson Andersen</dc:creator>
<dc:creator>Jacob Eiffer Møller</dc:creator>
<dc:creator>Henrik Vase</dc:creator>
<dc:creator>Mads Kristian Ersbøll</dc:creator>
<dc:creator>Steen Hvitfeldt Poulsen</dc:creator>
<dc:date>2024-04-03</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Challenges in Noninvasive Cardiac Output Assessment During Exercise</dc:title>
<dc:identifier>pmid:38569767</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.12.038</dc:identifier>
</item>
<item>
<title>Correction</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38569766/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240405001211&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Apr 9;83(14):1351. doi: 10.1016/j.jacc.2024.02.032.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38569766/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240405001211&v=2.18.0.post9+e462414">38569766</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.02.032>10.1016/j.jacc.2024.02.032</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38569766</guid>
<pubDate>Wed, 03 Apr 2024 06:00:00 -0400</pubDate>
<dc:date>2024-04-03</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Correction</dc:title>
<dc:identifier>pmid:38569766</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.02.032</dc:identifier>
</item>
<item>
<title>Age-Related Usage of GLP-1 Agonists in Obese Patients With Heart Failure and Preserved Ejection Fraction</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38569765/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240405001211&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Apr 9;83(14):1348-1350. doi: 10.1016/j.jacc.2024.01.033.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38569765/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240405001211&v=2.18.0.post9+e462414">38569765</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.01.033>10.1016/j.jacc.2024.01.033</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38569765</guid>
<pubDate>Wed, 03 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Aditya Achanta</dc:creator>
<dc:creator>Lauren Belak</dc:creator>
<dc:creator>Christine S Ritchie</dc:creator>
<dc:creator>James L Januzzi</dc:creator>
<dc:creator>Jason H Wasfy</dc:creator>
<dc:date>2024-04-03</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Age-Related Usage of GLP-1 Agonists in Obese Patients With Heart Failure and Preserved Ejection Fraction</dc:title>
<dc:identifier>pmid:38569765</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.01.033</dc:identifier>
</item>
<item>
<title>Strategies to Improve Patient-Centered Care for Drug Use-Associated Infective Endocarditis: JACC Focus Seminar 2/4</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38569764/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240405001211&amp;v=2.18.0.post9+e462414
      <description>Drug use-associated infective endocarditis (DUA-IE) is a major cause of illness and death for people with substance use disorder (SUD). Investigations to date have largely focused on advancing the care of patients with DUA-IE and included drug use disorder treatment, decisions about surgery, and choice of antibiotics during the period of hospitalization. Transitions from hospital to outpatient care are relatively unstudied and frequently a key factor of uncontrolled infection, continued...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Apr 9;83(14):1338-1347. doi: 10.1016/j.jacc.2024.01.034.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Drug use-associated infective endocarditis (DUA-IE) is a major cause of illness and death for people with substance use disorder (SUD). Investigations to date have largely focused on advancing the care of patients with DUA-IE and included drug use disorder treatment, decisions about surgery, and choice of antibiotics during the period of hospitalization. Transitions from hospital to outpatient care are relatively unstudied and frequently a key factor of uncontrolled infection, continued substance use, and death. In this paper, we review the evidence supporting cross-disciplinary care for people with DUA-IE and highlight domains that need further clinician, institutional, and research investment in clinicians and institutions. We highlight best practices for treating people with DUA-IE, with a focus on addressing health disparities, meeting health-related social needs, and policy changes that can support care for people with DUA-IE in the hospital and when transitioning to the community.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38569764/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240405001211&v=2.18.0.post9+e462414">38569764</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.01.034>10.1016/j.jacc.2024.01.034</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38569764</guid>
<pubDate>Wed, 03 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Alysse G Wurcel</dc:creator>
<dc:creator>Joji Suzuki</dc:creator>
<dc:creator>Asher J Schranz</dc:creator>
<dc:creator>Ellen F Eaton</dc:creator>
<dc:creator>Nicolas Cortes-Penfield</dc:creator>
<dc:creator>Larry M Baddour</dc:creator>
<dc:date>2024-04-03</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Strategies to Improve Patient-Centered Care for Drug Use-Associated Infective Endocarditis: JACC Focus Seminar 2/4</dc:title>
<dc:identifier>pmid:38569764</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.01.034</dc:identifier>
</item>
<item>
<title>Infective Endocarditis Involving Implanted Cardiac Electronic Devices: JACC Focus Seminar 1/4</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38569763/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240405001211&amp;v=2.18.0.post9+e462414
      <description>Cardiac implantable electronic device-related infective endocarditis (CIED-IE) encompasses a range of clinical syndromes, including valvular, device lead, and bloodstream infections. However, accurately diagnosing CIED-IE remains challenging owing in part to diverse clinical presentations, lack of standardized definition, and variations in guideline recommendations. Furthermore, current diagnostic modalities, such as transesophageal echocardiography and [^(18)F]-fluorodeoxyglucose positron...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Apr 9;83(14):1326-1337. doi: 10.1016/j.jacc.2023.11.036.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Cardiac implantable electronic device-related infective endocarditis (CIED-IE) encompasses a range of clinical syndromes, including valvular, device lead, and bloodstream infections. However, accurately diagnosing CIED-IE remains challenging owing in part to diverse clinical presentations, lack of standardized definition, and variations in guideline recommendations. Furthermore, current diagnostic modalities, such as transesophageal echocardiography and [<sup>18</sup>F]-fluorodeoxyglucose positron emission tomography-computed tomography have limited sensitivity and specificity, further contributing to diagnostic uncertainty. This can potentially result in complications and unnecessary costs associated with inappropriate device extraction. Six hypothetical clinical cases that exemplify the diverse manifestations of CIED-IE are addressed herein. Through these cases, we highlight the importance of optimizing diagnostic accuracy and stewardship, understanding different pathogen-specific risks for bloodstream infections, guiding appropriate device extraction, and preventing CIED-IE, all while addressing key knowledge gaps. This review both informs clinicians and underscores crucial areas for future investigation, thereby shedding light on this complex and challenging syndrome.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38569763/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240405001211&v=2.18.0.post9+e462414">38569763</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.11.036>10.1016/j.jacc.2023.11.036</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38569763</guid>
<pubDate>Wed, 03 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Supavit Chesdachai</dc:creator>
<dc:creator>Zerelda Esquer Garrigos</dc:creator>
<dc:creator>Christopher V DeSimone</dc:creator>
<dc:creator>Daniel C DeSimone</dc:creator>
<dc:creator>Larry M Baddour</dc:creator>
<dc:date>2024-04-03</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Infective Endocarditis Involving Implanted Cardiac Electronic Devices: JACC Focus Seminar 1/4</dc:title>
<dc:identifier>pmid:38569763</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.11.036</dc:identifier>
</item>
<item>
<title>Today's Infective Endocarditis: Not What You Learned in Medical School</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38569762/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240405001211&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Apr 9;83(14):1324-1325. doi: 10.1016/j.jacc.2024.02.025.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38569762/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240405001211&v=2.18.0.post9+e462414">38569762</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.02.025>10.1016/j.jacc.2024.02.025</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38569762</guid>
<pubDate>Wed, 03 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Larry M Baddour</dc:creator>
<dc:creator>Valentin Fuster</dc:creator>
<dc:date>2024-04-03</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Today's Infective Endocarditis: Not What You Learned in Medical School</dc:title>
<dc:identifier>pmid:38569762</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.02.025</dc:identifier>
</item>
<item>
<title>Real-World Experience With the Harmony Valve: Great Results for a Common Problem</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38569761/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240405001211&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Apr 9;83(14):1322-1323. doi: 10.1016/j.jacc.2024.02.027.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38569761/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240405001211&v=2.18.0.post9+e462414">38569761</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.02.027>10.1016/j.jacc.2024.02.027</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38569761</guid>
<pubDate>Wed, 03 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Mary B Taylor</dc:creator>
<dc:date>2024-04-03</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Real-World Experience With the Harmony Valve: Great Results for a Common Problem</dc:title>
<dc:identifier>pmid:38569761</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.02.027</dc:identifier>
</item>
<item>
<title>Early Outcomes From a Multicenter Transcatheter Self-Expanding Pulmonary Valve Replacement Registry</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38569760/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240405001211&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: In this large multicenter real-world experience, short-term clinical and hemodynamic outcomes of self-expanding TPVR therapy were excellent. Ongoing follow-up of this cohort will provide important insights into long-term outcomes.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Apr 9;83(14):1310-1321. doi: 10.1016/j.jacc.2024.02.010.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Transcatheter pulmonary valve replacement (TPVR) with the self-expanding Harmony valve (Medtronic) is an emerging treatment for patients with native or surgically repaired right ventricular outflow tract (RVOT) pulmonary regurgitation (PR). Limited data are available since U.S. Food and Drug Administration approval in 2021.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: In this study, the authors sought to evaluate the safety and short-term effectiveness of self-expanding TPVR in a real-world experience.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: This was a multicenter registry study of consecutive patients with native RVOT PR who underwent TPVR through April 30, 2022, at 11 U.S.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CENTERS: The primary outcome was a composite of hemodynamic dysfunction (PR greater than mild and RVOT mean gradient >;30 mm Hg) and RVOT reintervention.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 243 patients underwent TPVR at a median age of 31 years (Q1-Q3: 19-45 years). Cardiac diagnoses were tetralogy of Fallot (71%), valvular pulmonary stenosis (21%), and other (8%). Acute technical success was achieved in all but 1 case. Procedural serious adverse events occurred in 4% of cases, with no device embolization or death. Hospital length of stay was 1 day in 86% of patients. Ventricular arrhythmia prompting treatment occurred in 19% of cases. At a median follow-up of 13 months (Q1-Q3: 8-19 months), 98% of patients had acceptable hemodynamic function. Estimated freedom from the composite clinical outcome was 99% at 1 year and 96% at 2 years. Freedom from TPVR-related endocarditis was 98% at 1 year. Five patients died from COVID-19 (n = 1), unknown causes (n = 2), and bloodstream infection (n = 2).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In this large multicenter real-world experience, short-term clinical and hemodynamic outcomes of self-expanding TPVR therapy were excellent. Ongoing follow-up of this cohort will provide important insights into long-term outcomes.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38569760/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240405001211&v=2.18.0.post9+e462414">38569760</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.02.010>10.1016/j.jacc.2024.02.010</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38569760</guid>
<pubDate>Wed, 03 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Bryan H Goldstein</dc:creator>
<dc:creator>Doff B McElhinney</dc:creator>
<dc:creator>Matthew J Gillespie</dc:creator>
<dc:creator>Jamil A Aboulhosn</dc:creator>
<dc:creator>Daniel S Levi</dc:creator>
<dc:creator>Brian H Morray</dc:creator>
<dc:creator>Allison K Cabalka</dc:creator>
<dc:creator>Barry A Love</dc:creator>
<dc:creator>Jeffrey D Zampi</dc:creator>
<dc:creator>David T Balzer</dc:creator>
<dc:creator>Mark A Law</dc:creator>
<dc:creator>Mary D Schiff</dc:creator>
<dc:creator>Arvind Hoskoppal</dc:creator>
<dc:creator>Athar M Qureshi</dc:creator>
<dc:date>2024-04-03</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Early Outcomes From a Multicenter Transcatheter Self-Expanding Pulmonary Valve Replacement Registry</dc:title>
<dc:identifier>pmid:38569760</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.02.010</dc:identifier>
</item>
<item>
<title>Early SGLT2 Inhibitors in Acute Heart Failure: Safe Diuretic-Sparing Strategy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38569759/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240405001211&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Apr 9;83(14):1307-1309. doi: 10.1016/j.jacc.2024.02.012.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38569759/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240405001211&v=2.18.0.post9+e462414">38569759</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.02.012>10.1016/j.jacc.2024.02.012</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38569759</guid>
<pubDate>Wed, 03 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Maria Rosa Costanzo</dc:creator>
<dc:creator>James L Januzzi</dc:creator>
<dc:date>2024-04-03</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Early SGLT2 Inhibitors in Acute Heart Failure: Safe Diuretic-Sparing Strategy</dc:title>
<dc:identifier>pmid:38569759</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.02.012</dc:identifier>
</item>
<item>
<title>Efficacy and Safety of Dapagliflozin in Patients With Acute Heart Failure</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38569758/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240405001211&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Early dapagliflozin during AHF hospitalization is safe and fulfills a component of GDMT optimization. Dapagliflozin was not associated with a statistically significant reduction in weight-based diuretic efficiency but was associated with evidence for enhanced diuresis among patients with AHF. (Efficacy and Safety of Dapagliflozin in Acute Heart Failure [DICTATE-AHF]; NCT04298229).</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Apr 9;83(14):1295-1306. doi: 10.1016/j.jacc.2024.02.009.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: The primary goals during acute heart failure (AHF) hospitalization are decongestion and guideline-directed medical therapy (GDMT) optimization. Unlike diuretics or other GDMT, early dapagliflozin initiation could achieve both AHF goals.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The authors aimed to assess the diuretic efficacy and safety of early dapagliflozin initiation in AHF.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: In a multicenter, open-label study, 240 patients were randomized within 24 hours of hospital presentation for hypervolemic AHF to dapagliflozin 10 mg once daily or structured usual care with protocolized diuretic titration until day 5 or hospital discharge. The primary outcome, diuretic efficiency expressed as cumulative weight change per cumulative loop diuretic dose, was compared across treatment assignment using a proportional odds model adjusted for baseline weight. Secondary and safety outcomes were adjudicated by a blinded committee.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: For diuretic efficiency, there was no difference between dapagliflozin and usual care (OR: 0.65; 95% CI: 0.41-1.02; P = 0.06). Dapagliflozin was associated with reduced loop diuretic doses (560 mg [Q1-Q3: 260-1,150 mg] vs 800 mg [Q1-Q3: 380-1,715 mg]; P = 0.006) and fewer intravenous diuretic up-titrations (P ≤ 0.05) to achieve equivalent weight loss as usual care. Early dapagliflozin initiation did not increase diabetic, renal, or cardiovascular safety events. Dapagliflozin was associated with improved median 24-hour natriuresis (P = 0.03) and urine output (P = 0.005), expediting hospital discharge over the study period.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Early dapagliflozin during AHF hospitalization is safe and fulfills a component of GDMT optimization. Dapagliflozin was not associated with a statistically significant reduction in weight-based diuretic efficiency but was associated with evidence for enhanced diuresis among patients with AHF. (Efficacy and Safety of Dapagliflozin in Acute Heart Failure [DICTATE-AHF]; NCT04298229).</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38569758/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240405001211&v=2.18.0.post9+e462414">38569758</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.02.009>10.1016/j.jacc.2024.02.009</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38569758</guid>
<pubDate>Wed, 03 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Zachary L Cox</dc:creator>
<dc:creator>Sean P Collins</dc:creator>
<dc:creator>Gabriel A Hernandez</dc:creator>
<dc:creator>A Thomas McRae</dc:creator>
<dc:creator>Beth T Davidson</dc:creator>
<dc:creator>Kirkwood Adams</dc:creator>
<dc:creator>Mark Aaron</dc:creator>
<dc:creator>Luke Cunningham</dc:creator>
<dc:creator>Cathy A Jenkins</dc:creator>
<dc:creator>Christopher J Lindsell</dc:creator>
<dc:creator>Frank E Harrell</dc:creator>
<dc:creator>Christina Kampe</dc:creator>
<dc:creator>Karen F Miller</dc:creator>
<dc:creator>William B Stubblefield</dc:creator>
<dc:creator>JoAnn Lindenfeld</dc:creator>
<dc:date>2024-04-03</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Efficacy and Safety of Dapagliflozin in Patients With Acute Heart Failure</dc:title>
<dc:identifier>pmid:38569758</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.02.009</dc:identifier>
</item>
<item>
<title>Transcatheter Myotomy for LVOT Challenges: SESAME Street 2.0</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38569757/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240405001211&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Apr 9;83(14):1273-1275. doi: 10.1016/j.jacc.2024.02.033.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38569757/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240405001211&v=2.18.0.post9+e462414">38569757</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.02.033>10.1016/j.jacc.2024.02.033</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38569757</guid>
<pubDate>Wed, 03 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Georg Nickenig</dc:creator>
<dc:creator>Atsushi Sugiura</dc:creator>
<dc:date>2024-04-03</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Transcatheter Myotomy for LVOT Challenges: SESAME Street 2.0</dc:title>
<dc:identifier>pmid:38569757</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.02.033</dc:identifier>
</item>
<item>
<title>Gut microbiome and metabolome profiling in Framingham heart study reveals cholesterol-metabolizing bacteria</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38569543/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240405001211&amp;v=2.18.0.post9+e462414
      <description>Accumulating evidence suggests that cardiovascular disease (CVD) is associated with an altered gut microbiome. Our understanding of the underlying mechanisms has been hindered by lack of matched multi-omic data with diagnostic biomarkers. To comprehensively profile gut microbiome contributions to CVD, we generated stool metagenomics and metabolomics from 1,429 Framingham Heart Study participants. We identified blood lipids and cardiovascular health measurements associated with microbiome and...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Mar 21:S0092-8674(24)00305-2. doi: 10.1016/j.cell.2024.03.014. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Accumulating evidence suggests that cardiovascular disease (CVD) is associated with an altered gut microbiome. Our understanding of the underlying mechanisms has been hindered by lack of matched multi-omic data with diagnostic biomarkers. To comprehensively profile gut microbiome contributions to CVD, we generated stool metagenomics and metabolomics from 1,429 Framingham Heart Study participants. We identified blood lipids and cardiovascular health measurements associated with microbiome and metabolome composition. Integrated analysis revealed microbial pathways implicated in CVD, including flavonoid, γ-butyrobetaine, and cholesterol metabolism. Species from the Oscillibacter genus were associated with decreased fecal and plasma cholesterol levels. Using functional prediction and in vitro characterization of multiple representative human gut Oscillibacter isolates, we uncovered conserved cholesterol-metabolizing capabilities, including glycosylation and dehydrogenation. These findings suggest that cholesterol metabolism is a broad property of phylogenetically diverse Oscillibacter spp., with potential benefits for lipid homeostasis and cardiovascular health.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38569543/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240405001211&v=2.18.0.post9+e462414">38569543</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.03.014>10.1016/j.cell.2024.03.014</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38569543</guid>
<pubDate>Wed, 03 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Chenhao Li</dc:creator>
<dc:creator>Martin Stražar</dc:creator>
<dc:creator>Ahmed M T Mohamed</dc:creator>
<dc:creator>Julian A Pacheco</dc:creator>
<dc:creator>Rebecca L Walker</dc:creator>
<dc:creator>Tina Lebar</dc:creator>
<dc:creator>Shijie Zhao</dc:creator>
<dc:creator>Julia Lockart</dc:creator>
<dc:creator>Andrea Dame</dc:creator>
<dc:creator>Kumar Thurimella</dc:creator>
<dc:creator>Sarah Jeanfavre</dc:creator>
<dc:creator>Eric M Brown</dc:creator>
<dc:creator>Qi Yan Ang</dc:creator>
<dc:creator>Brittany Berdy</dc:creator>
<dc:creator>Dallis Sergio</dc:creator>
<dc:creator>Rachele Invernizzi</dc:creator>
<dc:creator>Antonio Tinoco</dc:creator>
<dc:creator>Gleb Pishchany</dc:creator>
<dc:creator>Ramachandran S Vasan</dc:creator>
<dc:creator>Emily Balskus</dc:creator>
<dc:creator>Curtis Huttenhower</dc:creator>
<dc:creator>Hera Vlamakis</dc:creator>
<dc:creator>Clary Clish</dc:creator>
<dc:creator>Stanley Y Shaw</dc:creator>
<dc:creator>Damian R Plichta</dc:creator>
<dc:creator>Ramnik J Xavier</dc:creator>
<dc:date>2024-04-03</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Gut microbiome and metabolome profiling in Framingham heart study reveals cholesterol-metabolizing bacteria</dc:title>
<dc:identifier>pmid:38569543</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.03.014</dc:identifier>
</item>
<item>
<title>Charting the cellular biogeography in colitis reveals fibroblast trajectories and coordinated spatial remodeling</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38569542/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240405001211&amp;v=2.18.0.post9+e462414
      <description>Gut inflammation involves contributions from immune and non-immune cells, whose interactions are shaped by the spatial organization of the healthy gut and its remodeling during inflammation. The crosstalk between fibroblasts and immune cells is an important axis in this process, but our understanding has been challenged by incomplete cell-type definition and biogeography. To address this challenge, we used multiplexed error-robust fluorescence in situ hybridization (MERFISH) to profile the...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Apr 1:S0092-8674(24)00254-X. doi: 10.1016/j.cell.2024.03.013. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Gut inflammation involves contributions from immune and non-immune cells, whose interactions are shaped by the spatial organization of the healthy gut and its remodeling during inflammation. The crosstalk between fibroblasts and immune cells is an important axis in this process, but our understanding has been challenged by incomplete cell-type definition and biogeography. To address this challenge, we used multiplexed error-robust fluorescence in situ hybridization (MERFISH) to profile the expression of 940 genes in 1.35 million cells imaged across the onset and recovery from a mouse colitis model. We identified diverse cell populations, charted their spatial organization, and revealed their polarization or recruitment in inflammation. We found a staged progression of inflammation-associated tissue neighborhoods defined, in part, by multiple inflammation-associated fibroblasts, with unique expression profiles, spatial localization, cell-cell interactions, and healthy fibroblast origins. Similar signatures in ulcerative colitis suggest conserved human processes. Broadly, we provide a framework for understanding inflammation-induced remodeling in the gut and other tissues.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38569542/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240405001211&v=2.18.0.post9+e462414">38569542</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.03.013>10.1016/j.cell.2024.03.013</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38569542</guid>
<pubDate>Wed, 03 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Paolo Cadinu</dc:creator>
<dc:creator>Kisha N Sivanathan</dc:creator>
<dc:creator>Aditya Misra</dc:creator>
<dc:creator>Rosalind J Xu</dc:creator>
<dc:creator>Davide Mangani</dc:creator>
<dc:creator>Evan Yang</dc:creator>
<dc:creator>Joseph M Rone</dc:creator>
<dc:creator>Katherine Tooley</dc:creator>
<dc:creator>Yoon-Chul Kye</dc:creator>
<dc:creator>Lloyd Bod</dc:creator>
<dc:creator>Ludwig Geistlinger</dc:creator>
<dc:creator>Tyrone Lee</dc:creator>
<dc:creator>Randall T Mertens</dc:creator>
<dc:creator>Noriaki Ono</dc:creator>
<dc:creator>Gang Wang</dc:creator>
<dc:creator>Liliana Sanmarco</dc:creator>
<dc:creator>Francisco J Quintana</dc:creator>
<dc:creator>Ana C Anderson</dc:creator>
<dc:creator>Vijay K Kuchroo</dc:creator>
<dc:creator>Jeffrey R Moffitt</dc:creator>
<dc:creator>Roni Nowarski</dc:creator>
<dc:date>2024-04-03</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Charting the cellular biogeography in colitis reveals fibroblast trajectories and coordinated spatial remodeling</dc:title>
<dc:identifier>pmid:38569542</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.03.013</dc:identifier>
</item>
<item>
<title>Cardio-obstetrics: a new specialty</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38569057/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240405001211&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Apr 3:ehae202. doi: 10.1093/eurheartj/ehae202. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38569057/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240405001211&v=2.18.0.post9+e462414">38569057</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae202>10.1093/eurheartj/ehae202</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38569057</guid>
<pubDate>Wed, 03 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Eugene Braunwald</dc:creator>
<dc:date>2024-04-03</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Cardio-obstetrics: a new specialty</dc:title>
<dc:identifier>pmid:38569057</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae202</dc:identifier>
</item>





























</channel>
</rss>